Satya Yendluri

Summary

Affiliation: Cell Genesys
Country: USA

Publications

  1. ncbi request reprint AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma
    Thomas C Harding
    Cell Genesys, Inc, 500 Forbes Boulevard, South San Francisco, CA 94080, USA
    Mol Ther 13:956-66. 2006
  2. ncbi request reprint Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors
    Thomas C Harding
    Cell Genesys, South San Francisco, CA 94080, USA
    Hum Gene Ther 17:807-20. 2006
  3. pmc Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors
    Michael Robinson
    Cell Genesys, Inc, 500 Forbes Blvd, South San Francisco, CA 94080, USA
    J Virol 83:3450-62. 2009
  4. ncbi request reprint Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy
    Kate L Dishart
    Division of Cardiovascular and Medical Sciences, University of Glasgow, Church Street, G11 6NT, Glasgow, UK
    J Mol Cell Cardiol 35:739-48. 2003

Collaborators

  • Betty Li
  • Andrew H Baker
  • Thomas C Harding
  • Michael Robinson
  • Karin Jooss
  • Byron N Roberts
  • Peter J Dickinson
  • Thomas Harding
  • Melissa Gonzalez-Edick
  • Kate L Dishart
  • Melinda VanRoey
  • Ying Ge
  • Katherine R Spindler
  • Derek Ko
  • Richard A LeCouter
  • Kathryn E Koprivnikar
  • Bo Luan
  • Dennis Deen
  • Karin U Jooss
  • Tomoko Ozawa
  • Melinda J VanRoey
  • Guang Huan-Tu
  • Richard A LeCouteur
  • Randy Musterer
  • Alshad S Lalani
  • Melanie J Tuerk
  • Brian A Donahue
  • Sarah J George
  • Andrew C Newby
  • Laura Denby
  • Stuart A Nicklin
  • Michael P Kelley

Detail Information

Publications4

  1. ncbi request reprint AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma
    Thomas C Harding
    Cell Genesys, Inc, 500 Forbes Boulevard, South San Francisco, CA 94080, USA
    Mol Ther 13:956-66. 2006
    ..We propose that rAAV-mediated gene transfer of a potent soluble VEGF inhibitor in the CNS represents an effective antiangiogenic treatment strategy for GBM...
  2. ncbi request reprint Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors
    Thomas C Harding
    Cell Genesys, South San Francisco, CA 94080, USA
    Hum Gene Ther 17:807-20. 2006
    ....
  3. pmc Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors
    Michael Robinson
    Cell Genesys, Inc, 500 Forbes Blvd, South San Francisco, CA 94080, USA
    J Virol 83:3450-62. 2009
    ....
  4. ncbi request reprint Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy
    Kate L Dishart
    Division of Cardiovascular and Medical Sciences, University of Glasgow, Church Street, G11 6NT, Glasgow, UK
    J Mol Cell Cardiol 35:739-48. 2003
    ..We have demonstrated for the first time the potential for third-generation lentiviral vectors, but not alternate AAV serotypes, as efficient vascular gene delivery vectors...